Ladenburg Thalmann Maintains Buy on Checkpoint Therapeutics, Lowers Price Target to $47
Portfolio Pulse from jenniferd'souza@benzinga.com
Ladenburg Thalmann analyst Jeffrey Cohen maintains a 'Buy' rating on Checkpoint Therapeutics (NASDAQ:CKPT), but has lowered the price target from $65 to $47.
August 15, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Checkpoint Therapeutics' price target has been lowered from $65 to $47 by Ladenburg Thalmann, though the 'Buy' rating is maintained.
While the lowering of the price target might initially seem negative, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100